As of November 7, 2026, Cardiff Oncology, Inc. has Schedule 13D or 13G filings on record, none whose latest reports a stake of 5% or more. 4 filings are on record since July 29, 2025 (Schedule 13G/A, July 27, 2026).
Sell to companies like Cardiff Oncology, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: BlackRock, Inc. · Sole voting: 863,259 · Shared voting: 0 · Sole dispositive: 863,259 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-27
- · Holder: The Vanguard Group · Percent: 0% · SCHEDULE 13G/A
- · Holder: Commodore Capital LP · Percent: 0% · SCHEDULE 13G/A
- · Holder: The Vanguard Group · Percent: 5.6% · SCHEDULE 13G
Cardiff Oncology, Inc. has 4 Schedule 13D or 13G filings on record since 2025-07-29. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock, Inc. | 1.3% | 863,259 | SCHEDULE 13G/A, 2026-07-27 | 2026-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
| Commodore Capital LP | 0% | 0 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
Holding shares or following this stake? See who's behind Cardiff Oncology, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Cardiff Oncology, Inc. and the records around it.
Cardiff Oncology, Inc. elsewhere on the record
- Leadership changes Apr 2026
- Who owns it
Companies that share a holder
- Commodore Capital LP also filed stake reports on 40 other companies: Sagimet Biosciences Inc. (Oct 2026), Surrozen, Inc./DE (Oct 2026), JATT III Acquisition Corp (Sep 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Cardiff Oncology, Inc.
Get an email when Cardiff Oncology, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cardiff Oncology, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Cardiff Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cardiff Oncology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 863,259 | 0 | 863,259 | 0 | SCHEDULE 13G/A, 2026-07-27 |
The latest filing identifies Cardiff Oncology, Inc. by CUSIP 14147L108 and gives its principal executive office as 11055 FLINTKOTE AVENUE, SAN DIEGO, CA 92121 (SCHEDULE 13G/A, 2026-07-27).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-29 | The Vanguard Group | 5.6% | SCHEDULE 13G |
| 2025-08-14 | Commodore Capital LP | 0% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-07-27 | BlackRock, Inc. | 1.3% | SCHEDULE 13G/A |
Also on the record for Cardiff Oncology, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Leadership change: Leila Alland appointed, Chief Medical Officer | — | Leadership changes | Source |
| April 9, 2026 | Leadership change: Josh Muntner appointed, Chief Financial Officer | — | Leadership changes | Source |
| April 2, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Cardiff Oncology, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.